The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.

A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA).

Not all physicians who treat Alzheimer's disease will prescribe the new Alzheimer's drug aducanumab (Aduhelm) -- major hospital systems like the Cleveland Clinic and Mount Sinai in New York City, for example, won't administer the controversial treatment -- but those who will offer the drug need more information about how to use it, a panel of neuroscientists said.

Appropriate use recommendations for the newly approved Alzheimer disease treatment, aducanumab (Aduhelm; Biogen, Cambridge, MA) have been published in The Journal of Prevention of Alzheimer’s Disease (JPAD).

A group of six leading Alzheimer’s experts have convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease.

Just a month after it gave the new Alzheimer's drug aducanumab (Aduhelm) the green light, the FDA decided to change the label.

In a watershed moment for the field, the U.S. Food and Drug Administration yesterday approved the first Alzheimer’s treatment that tackles the underlying disease pathology.

Aducanumab is the first disease-modifying treatment to be approved for Alzheimer's Disease (AD) and the first to target amyloid ß (Aß), which is one of the earliest causative steps in the pathophysiology of AD.